title: Letter: should anti-viral therapy be recommended for individuals chronically infected with hepatitis B virus and at low risk of hepatocellular carcinoma?
authors.affiliation: Experimental Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: C-Y
authors.initials: CY
authors.lastname: Zhang
authors.affiliation: Department of Hepatobiliary Surgery, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, China.
authors.forename: Z-H
authors.initials: ZH
authors.lastname: He
authors.affiliation: Section of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
authors.forename: B-K
authors.initials: BK
authors.lastname: Ahir
authors.affiliation: Experimental Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: C-P
authors.initials: CP
authors.lastname: Luo
authors.affiliation: Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: N-F
authors.initials: NF
authors.lastname: Peng
authors.affiliation: Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: L-Q
authors.initials: LQ
authors.lastname: Li
mesh_terms: D000998:Antiviral Agents; D006528:Carcinoma, Hepatocellular / Q000821:virology*; D006509:Hepatitis B; D006515:Hepatitis B virus; D006801:Humans; D008113:Liver Neoplasms / Q000821:virology
chemical_list: D000998:Antiviral Agents